Related Experiment Video

Updated: Jun 12, 2026

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses

C Siddiq Abdul-Alim1, Yongqing Li, Cassian Yee

  • 1Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Journal of Immunology (Baltimore, Md. : 1950)
|May 21, 2010
PubMed

Insights

Researchers identified novel superagonist altered peptide ligands (APLs) that enhance cytotoxic T-lymphocyte (CTL) responses against tumors. These APLs show patient-specific effectiveness, supporting personalized cancer vaccines.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Cytotoxic T-lymphocytes (CTLs) are crucial for anti-tumor immunity.
  • Superagonist altered peptide ligands (APLs) can improve CTL responses against tumor-associated antigens.
  • Existing methods for identifying superagonist APLs are limited.

Purpose of the Study:

  • To develop a comprehensive screening strategy for identifying novel superagonist APLs.
  • To investigate supraoptimal superagonists of the 27L MART-1 mutant.
  • To assess the patient-specific efficacy of identified superagonist APLs.

Main Methods:

  • Utilized a novel genetic screen involving recombinant technology and class I antigen cross-presentation.
  • Surveyed single amino acid substitution mutants of the 27L MART-1 mutant.
  • Tested mutant epitope effectiveness in activating human antigen-specific CTL clones recognizing MART-1(26-35).

Main Results:

  • Identified three novel mutant epitopes with superagonist properties superior to the 27L mutant.
  • Demonstrated that superagonist efficacy varies significantly among patients.
  • Found that specific superagonist APLs may be best suited for individual patients.

Conclusions:

  • Comprehensive screening methods are essential for discovering potent superagonist APLs.
  • Patient-specific responses highlight the need for personalized approaches in tumor peptide vaccination.
  • Superagonist APLs hold promise for enhancing CTL-mediated anti-tumor immunity.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...